Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 295, Issue 2, 2008, Pages

  Reidelberger, Roger D ^a,b,c   Haver, Alvin C ^a,b   Chelikani, Prasanth K ^b,d   Buescher, James L ^b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA NWIHCS ^*  (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anorexia; Body composition; Gastrointestinal; Intraperitoneal administration; Peptide

Indexed keywords

PEPTIDE YY [3-36]; ANOREXIGENIC AGENT; PEPTIDE YY; PEPTIDE YY (3 36);

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FOOD INTAKE; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; WEIGHT GAIN; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG ADMINISTRATION; EATING; FAT INTAKE; HOMEOSTASIS; INFUSION; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ADIPOSITY; ANIMALS; APPETITE DEPRESSANTS; BEHAVIOR, ANIMAL; BODY WEIGHT; DIETARY FATS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EATING; HOMEOSTASIS; INFUSIONS, PARENTERAL; MALE; OBESITY; PEPTIDE YY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 51149109600     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00040.2008     Document Type: Article

References (37)

1. Adams SH, Lei C, Jodka CM, Nikoulina SE, Hoyt JA, Gedulin B, Mack CM, Kendall ES. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J Nutr 136: 195-201, 2006.
2. Al Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 8: 317-323, 2000.
3. Amblard M, Fehrentz JA, Martinez J, Subra G. Methods and protocols of modern solid phase peptide synthesis. Mol Biotechnol 33: 239-254, 2006.
4. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 404: 672-677, 2000.
5. Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290: R298-R305, 2006.
6. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146: 879-888, 2005.
7. Chelikani PK, Haver AC, Reidelberger RD. Dose-dependent effects of peptide YY(3-36) on conditioned taste aversion in rats. Peptides 27: 3193-3201, 2006.
8. Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293: R1798-R1808, 2007.
9. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293: R39-R46, 2007.
10. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302: 703-706, 1983.
11. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 117: 13-23, 2007.
12. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129: 1430-1436, 2005.
13. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 779: 75-83, 1998.
14. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 16: 717-742, 2002.
15. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 60: S1-S14, 2002.
16. Glass MJ, Billington CJ, Levine AS. Opioids and food intake: distributed functional neural pathways? Neuropeptides 33: 360-368, 1999.
17. Grady EF, Bohm SK, Bunnett NW. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol Gastrointest Liver Physiol 273: G586-G601, 1997.
18. Gura T. Obesity research: new data on appetite-suppressing peptide challenge critics. Science 306: 1453-1454, 2004.
19. Halatchev IG, Cone RD. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1: 159-168, 2005.
20. Ladenheim EE. Peptide YY(3-36) and food intake: a peptide waiting for a paradigm? Am J Physiol Regul Integr Comp Physiol 293: R37-R38, 2007.
21. Levin BE. Factors promoting and ameliorating the development of obesity. Physiol Behav 86: 633-639, 2005.
22. Lukaszewski L, Praissman M. Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats. Am J Physiol Regul Integr Comp Physiol 254: R17-R22, 1988.
23. Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, Vu C, Roth J, Parkes D. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 293: R1855-R1863, 2007.
24. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340, 2006.
25. Morley JE, Flood JF. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 41: 2157-2165, 1987.
26. Olsson M, Herrington MK, Reidelberger RD, Permert J, Arnelo U. Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. Peptides 28: 1416-1423, 2007.
27. Persson P. Highlights from the literature: What underlies the inability of several labs to reproduce the appetite suppressing effects of peptide YY(3-36) [PYY(3-36)]? Physiology 21: 4-5, 2006.
28. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51: 1337-1345, 2002.
29. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, Young AA. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28: 963-971, 2004.
30. Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148: 6054-6061, 2007.
31. Salva LP, Garcia Vicente JA, Costa PJ, Lucio MP. Causes and problems of nonresponse or poor response to drugs. Drugs 51: 552-570, 1996.
32. Seeley RJ, Burklow ML, Wilmer KA, Matthews CC, Reizes O, McOsker CC, Trokhan DP, Gross MC, Sheldon RJ. The effect of the melanocortin agonist, MT-II, on the defended level of body adiposity. Endocrinology 146: 3732-3738, 2005.
33. Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiol Rev 85: 1131-1158, 2005.
34. Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-Sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 1, 2004.
35. Unniappan S, Kieffer TJ. Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad lib fed rats. Am J Physiol Regul Integr Comp Physiol 295: R51-R58, 2008.
36. Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R, Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 49: 1915-1923, 2006.
37. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291: R367-R375, 2006.